Use of uniform end points among clinical
trials to facilitate meaningful comparisons between therapies |
Understanding the mechanisms and management of
persistent symptoms in spite of histologic remission |
Defining the extent and implications of
variations in clinical outcomes for individual patients |
Head-to-head studies comparing therapies to
inform an algorithmic approach |
Effectiveness of combinations of treatments
(eg, PPI + diet, PPI + steroids, steroids + diet, steroids +
dilation) |
Prospective data on the natural history of EoE
to inform decisions regarding maintenance therapy |
Longer-term studies evaluating the efficacy of
maintenance medical and diet therapies |
Measurement of quality of life and nutritional
status as outcomes |
Use of biomarkers for diagnosis and
monitoring |
Validation of office-based, nonendoscopic
disease-monitoring methods for EoE activity |
Appropriate timing of esophageal dilation in
relation to use of medical or diet therapy (eg, should esophageal
dilation only be performed after initiation of medical or diet
therapy) |
Using clinical history of symptoms with food
exposure to guide therapy in EoE |
Interaction between oral immunotherapy for
food allergy and EoE |
Impact of other associated atopic diseases
(IgE-mediated food allergy, pollen food allergy, atopic dermatitis,
asthma, allergic rhinitis) |
Effectiveness of environmental allergen
avoidance and immunotherapy |